Sign up to save your podcasts
Or
Share Novel Oral Agent Lowers HbA1c, Improves Beta-Cell Function in T2D
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Novel Oral Agent Lowers HbA1c, Improves Beta-Cell Function in T2D
A novel oral diabetes therapy shows durable HbA1c reduction and beta-cell preservation after short treatment, potentially shifting type 2 diabetes care toward disease-modifying, accessible, and longer-lasting management strategies.
View all episodes
By TheBrief.HealthA novel oral diabetes therapy shows durable HbA1c reduction and beta-cell preservation after short treatment, potentially shifting type 2 diabetes care toward disease-modifying, accessible, and longer-lasting management strategies.